Total Funding
89
69
Total FundingSeries D raised
Growth Score
0 pts
Heat Score
11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
13179
Neurelis is a specialty pharmaceutical company providing a highly differentiated approach to target unmet medical needs.
- David Hale: Executive Chairman/Co-FounderPast Role: Women First HealthCare, Inc., President and CEO
Craig Chambliss: Co-founder, CEO & PresidentPast Role: Xcel Pharmaceuticals, VP Sales and Marketing
About the Company
Neurelis is a specialty pharmaceutical company, licenses, develops, and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market. It provides a differentiated approach to target unmet medical needs. Their application of novel technologies is designed to enhance the therapeutic benefit and patient care.
The
company was incorporated in 2007 and is based in Encinitas, California.
